ALACHUA, Fla.--(BUSINESS WIRE)--AxoGen, Inc. (OTCBB: AXGN):
Second Quarter 2012 Highlights
• Record revenues of $2.01 million, a 64% increase from second quarter 2011
• Gross profit for second quarter 2012 increased 89% to a record $1.5 million
• Gross profit margins improved to 75% compared to 65% for the same period in 2011
AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced revenues for the second quarter ended June 30, 2012 of $2.01 million, a 64% increase over second quarter 2011 revenues of $1.65 million.